Literature DB >> 8444417

Administration of hepatic stimulatory substance alone or with other liver growth factors does not ameliorate acetaminophen-induced liver failure.

A Francavilla1, A Azzarone, G Carrieri, U Cillo, D Van Thiel, V Subbottin, T E Starzl.   

Abstract

Sixty-two beagle dogs were given three doses of acetaminophen over a period of 24 hr in a fulminant liver failure model that is 70% lethal in 72 hr. Treatment of the animals with hepatic stimulatory substance alone or in a mixture with insulin, transforming growth factor-alpha and insulin-like growth factor II had no effect on mortality. Evidence of maximum regeneration with a mitotic index 20 to 25 times resting was the same in treated and untreated animals. Similarly, the biochemical and hematological indexes of liver injury were unaffected by therapy. These studies illustrate the futility of treating fulminant liver failure with exogenous growth factors that apparently are already present in large amounts in the natural response to liver injury. The results suggest that on-going liver injury by mechanisms other than lack of growth factors is the central problem of fulminant liver failure. If so, provision of regeneration-stimulating substance is an inappropriate therapeutic strategy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8444417      PMCID: PMC2950635     

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  33 in total

Review 1.  Liver regeneration in relationship to acute liver failure.

Authors:  C D Gove; R D Hughes
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Coagulation defects.

Authors:  J H LEWIS
Journal:  JAMA       Date:  1961-12-09       Impact factor: 56.272

3.  Effect of insulin and glucagon on fulminant murine hepatitis.

Authors:  M Farivar; J R Wands; K J Isselbacher; N L Bucher
Journal:  N Engl J Med       Date:  1976-12-30       Impact factor: 91.245

4.  The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood.

Authors:  T E Starzl; A Francavilla; C G Halgrimson; F R Francavilla; K A Porter; T H Brown; C W Putnam
Journal:  Surg Gynecol Obstet       Date:  1973-08

5.  Further steps of hepatic stimulatory substance purification.

Authors:  A Francavilla; M Barone; D H Van Thiel; V Mazzaferro; J G Prelich; T E Starzl
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

6.  Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs.

Authors:  T E Starzl; K Watanabe; K A Porter; C W Putnam
Journal:  Lancet       Date:  1976-04-17       Impact factor: 79.321

7.  Analysis of proliferating hepatocytes using a monoclonal antibody against proliferating cell nuclear antigen/cyclin in embedded tissues from various liver diseases fixed in formaldehyde.

Authors:  N Kawakita; S Seki; H Sakaguchi; A Yanai; T Kuroki; Y Mizoguchi; K Kobayashi; T Monna
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

8.  Effect of cold preservation on lymphocyte adherence in the perfused rat liver.

Authors:  P A Clavien; G R Morgan; J R Sanabria; C Petrunka; G A Levy; P Robert; C Harvey; S M Strasberg
Journal:  Transplantation       Date:  1991-09       Impact factor: 4.939

9.  Screening for candidate hepatic growth factors by selective portal infusion after canine Eck's fistula.

Authors:  A Francavilla; T E Starzl; K Porter; C S Foglieni; G K Michalopoulos; G Carrieri; J Trejo; A Azzarone; M Barone; Q H Zeng
Journal:  Hepatology       Date:  1991-10       Impact factor: 17.425

10.  Portal hepatotrophic factors, diabetes mellitus and acute liver atrophy, hypertrophy and regeneration.

Authors:  T E Starzl; K A Porter; N Kashiwagi
Journal:  Surg Gynecol Obstet       Date:  1975-12
View more
  6 in total

1.  Hepatic stimulator substance activity in animal model of fulminant hepatic failure and encephalopathy.

Authors:  Alexandra P Margeli; Evangelos Manolis; Spyridon N Skaltsas; Kyriakos S Tsarpalis; Michael G Mykoniatis; Stamatios E Theocharis
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

Review 2.  Insights on augmenter of liver regeneration cloning and function.

Authors:  Elisavet Gatzidou; Gregory Kouraklis; Stamatios Theocharis
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

3.  Reduction of primary nonfunction with prostaglandin E1 after clinical liver transplantation.

Authors:  S Takaya; H Doyle; S Todo; W Irish; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1995-04       Impact factor: 1.066

Review 4.  Liver Regeneration after Acetaminophen Hepatotoxicity: Mechanisms and Therapeutic Opportunities.

Authors:  Bharat Bhushan; Udayan Apte
Journal:  Am J Pathol       Date:  2019-01-14       Impact factor: 4.307

5.  Levels of hepatic stimulator substance in liver regenerating process of partially hepatectomized rats pretreated with a single dose of carbon tetrachloride.

Authors:  A A Liakos; M G Mykoniatis; M E Kokala; D G Papadimitriou; G D Liatsos
Journal:  Dig Dis Sci       Date:  1999-05       Impact factor: 3.199

6.  Pro-regenerative signaling after acetaminophen-induced acute liver injury in mice identified using a novel incremental dose model.

Authors:  Bharat Bhushan; Chad Walesky; Michael Manley; Tara Gallagher; Prachi Borude; Genea Edwards; Satdarshan P S Monga; Udayan Apte
Journal:  Am J Pathol       Date:  2014-09-02       Impact factor: 4.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.